EXTENDED - TODAY ONLY: MarketBeat All Access For Just $399 $199 (save 50%)
×
QQQ   280.63 (-0.74%)
AAPL   141.25 (-2.06%)
MSFT   240.48 (-0.53%)
META   109.46 (+0.63%)
GOOGL   95.25 (-0.83%)
AMZN   92.45 (-1.60%)
TSLA   180.88 (-1.12%)
NVDA   156.44 (-1.16%)
NIO   10.52 (+3.95%)
BABA   79.80 (+5.17%)
AMD   73.41 (+0.30%)
T   19.02 (+1.06%)
MU   55.15 (-1.08%)
CGC   3.42 (+0.59%)
F   13.75 (+0.15%)
GE   85.65 (+0.21%)
DIS   94.71 (-1.02%)
AMC   7.47 (+1.91%)
PYPL   77.71 (-2.78%)
PFE   49.41 (-0.32%)
NFLX   281.03 (-0.05%)
QQQ   280.63 (-0.74%)
AAPL   141.25 (-2.06%)
MSFT   240.48 (-0.53%)
META   109.46 (+0.63%)
GOOGL   95.25 (-0.83%)
AMZN   92.45 (-1.60%)
TSLA   180.88 (-1.12%)
NVDA   156.44 (-1.16%)
NIO   10.52 (+3.95%)
BABA   79.80 (+5.17%)
AMD   73.41 (+0.30%)
T   19.02 (+1.06%)
MU   55.15 (-1.08%)
CGC   3.42 (+0.59%)
F   13.75 (+0.15%)
GE   85.65 (+0.21%)
DIS   94.71 (-1.02%)
AMC   7.47 (+1.91%)
PYPL   77.71 (-2.78%)
PFE   49.41 (-0.32%)
NFLX   281.03 (-0.05%)
QQQ   280.63 (-0.74%)
AAPL   141.25 (-2.06%)
MSFT   240.48 (-0.53%)
META   109.46 (+0.63%)
GOOGL   95.25 (-0.83%)
AMZN   92.45 (-1.60%)
TSLA   180.88 (-1.12%)
NVDA   156.44 (-1.16%)
NIO   10.52 (+3.95%)
BABA   79.80 (+5.17%)
AMD   73.41 (+0.30%)
T   19.02 (+1.06%)
MU   55.15 (-1.08%)
CGC   3.42 (+0.59%)
F   13.75 (+0.15%)
GE   85.65 (+0.21%)
DIS   94.71 (-1.02%)
AMC   7.47 (+1.91%)
PYPL   77.71 (-2.78%)
PFE   49.41 (-0.32%)
NFLX   281.03 (-0.05%)
QQQ   280.63 (-0.74%)
AAPL   141.25 (-2.06%)
MSFT   240.48 (-0.53%)
META   109.46 (+0.63%)
GOOGL   95.25 (-0.83%)
AMZN   92.45 (-1.60%)
TSLA   180.88 (-1.12%)
NVDA   156.44 (-1.16%)
NIO   10.52 (+3.95%)
BABA   79.80 (+5.17%)
AMD   73.41 (+0.30%)
T   19.02 (+1.06%)
MU   55.15 (-1.08%)
CGC   3.42 (+0.59%)
F   13.75 (+0.15%)
GE   85.65 (+0.21%)
DIS   94.71 (-1.02%)
AMC   7.47 (+1.91%)
PYPL   77.71 (-2.78%)
PFE   49.41 (-0.32%)
NFLX   281.03 (-0.05%)
NASDAQ:NTLA

Intellia Therapeutics - NTLA Stock Forecast, Price & News

$48.00
-0.26 (-0.54%)
(As of 11/29/2022 03:58 PM ET)
Add
Compare
Today's Range
$47.23
$49.60
50-Day Range
$48.26
$62.69
52-Week Range
$37.08
$130.33
Volume
31,277 shs
Average Volume
739,196 shs
Market Capitalization
$3.78 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$110.72

Intellia Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.83 Rating Score
Upside/​Downside
131.9% Upside
$110.72 Price Target
Short Interest
Healthy
8.45% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.67
Upright™ Environmental Score
News Sentiment
1.02mentions of Intellia Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($6.08) to ($5.96) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.72 out of 5 stars

Medical Sector

77th out of 1,038 stocks

Diagnostic Substances Industry

2nd out of 14 stocks

NTLA stock logo

About Intellia Therapeutics (NASDAQ:NTLA) Stock

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. In addition, it offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease; Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; Ospedale San Raffaele; and a strategic collaboration with SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases. The company was formerly known as AZRN, Inc. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Receive NTLA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Intellia Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

NTLA Stock News Headlines

Verve Therapeutics Crushed By Clinical Hold
SVB Securities Keeps Their Buy Rating on Intellia Therapeutics (NTLA)
Earnings Preview For Intellia Therapeutics
10 Best Gene Editing Stocks To Buy
Intellia Therapeutics Inc (38I)
Cathie Wood Is Loading Up on These 3 Stocks: Should You?
Crispr Gene-Editing Drugs Show Promise in Preliminary Study
See More Headlines
Receive NTLA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Intellia Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

NTLA Company Calendar

Last Earnings
11/03/2022
Today
11/29/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/23/2023

Industry, Sector and Symbol

Industry
Diagnostic substances
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:NTLA
Fax
N/A
Employees
485
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$110.72
High Stock Price Forecast
$180.00
Low Stock Price Forecast
$50.00
Forecasted Upside/Downside
+130.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.83
Research Coverage
18 Analysts

Profitability

Net Income
$-267,890,000.00
Net Margins
-859.92%
Pretax Margin
-859.92%

Debt

Sales & Book Value

Annual Sales
$33.05 million
Book Value
$14.15 per share

Miscellaneous

Free Float
76,638,000
Market Cap
$3.78 billion
Optionable
Optionable
Beta
1.83

Key Executives

  • Dr. John M. Leonard M.D.Dr. John M. Leonard M.D. (Age 65)
    Pres, CEO & Director
    Comp: $1.08M
  • Mr. Glenn G. Goddard CPAMr. Glenn G. Goddard CPA (Age 51)
    Exec. VP, CFO & Treasurer
    Comp: $663.01k
  • Dr. Laura Sepp-Lorenzino Ph.D.Dr. Laura Sepp-Lorenzino Ph.D. (Age 61)
    Exec. VP & Chief Scientific Officer
    Comp: $705.08k
  • Mr. James E. Basta Esq. (Age 56)
    J.D., Exec. VP, Gen. Counsel & Corp. Sec.
    Comp: $661.78k
  • Dr. David Lebwohl M.D.Dr. David Lebwohl M.D. (Age 67)
    Exec. VP & Chief Medical Officer
    Comp: $736.84k
  • Mr. Nessan Bermingham Ph.D. (Age 49)
    Founder & Member of Scientific Advisor Board
  • Dr. Rachel E. Haurwitz Ph.D. (Age 36)
    Co-Founder
  • Dr. Andrew May
    Founder and Member of Scientific Advisor Board
  • Dr. Jennifer A. Doudna Ph.D. (Age 58)
    Founder & Member of Scientific Advisor Board
  • Dr. Derrick J. Rossi Ph.D.
    Founder & Member of Scientific Advisor Board













NTLA Stock - Frequently Asked Questions

Should I buy or sell Intellia Therapeutics stock right now?

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intellia Therapeutics in the last twelve months. There are currently 1 sell rating, 1 hold rating and 16 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" NTLA shares.
View NTLA analyst ratings
or view top-rated stocks.

What is Intellia Therapeutics' stock price forecast for 2023?

18 brokerages have issued 12-month price targets for Intellia Therapeutics' shares. Their NTLA share price forecasts range from $50.00 to $180.00. On average, they anticipate the company's share price to reach $110.72 in the next twelve months. This suggests a possible upside of 129.4% from the stock's current price.
View analysts price targets for NTLA
or view top-rated stocks among Wall Street analysts.

How have NTLA shares performed in 2022?

Intellia Therapeutics' stock was trading at $118.24 at the start of the year. Since then, NTLA stock has decreased by 59.2% and is now trading at $48.26.
View the best growth stocks for 2022 here
.

When is Intellia Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023.
View our NTLA earnings forecast
.

How were Intellia Therapeutics' earnings last quarter?

Intellia Therapeutics, Inc. (NASDAQ:NTLA) issued its quarterly earnings results on Thursday, November, 3rd. The company reported ($1.49) EPS for the quarter, missing the consensus estimate of ($1.31) by $0.18. The business earned $13.27 million during the quarter, compared to the consensus estimate of $13.60 million. Intellia Therapeutics had a negative net margin of 859.92% and a negative trailing twelve-month return on equity of 47.79%.

What is John Leonard, M.D.'s approval rating as Intellia Therapeutics' CEO?

12 employees have rated Intellia Therapeutics Chief Executive Officer John Leonard, M.D. on Glassdoor.com. John Leonard, M.D. has an approval rating of 73% among the company's employees.

What other stocks do shareholders of Intellia Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Intellia Therapeutics investors own include Editas Medicine (EDIT), CRISPR Therapeutics (CRSP), NVIDIA (NVDA), Alibaba Group (BABA), Block (SQ), Micron Technology (MU), Advanced Micro Devices (AMD), Intel (INTC), Invitae (NVTA) and Cisco Systems (CSCO).

When did Intellia Therapeutics IPO?

(NTLA) raised $85 million in an IPO on Friday, May 6th 2016. The company issued 5,000,000 shares at $16.00-$18.00 per share. Credit Suisse, Jefferies and Leerink Partners served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What is Intellia Therapeutics' stock symbol?

Intellia Therapeutics trades on the NASDAQ under the ticker symbol "NTLA."

Who are Intellia Therapeutics' major shareholders?

Intellia Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include ARK Investment Management LLC (12.70%), Vanguard Group Inc. (8.41%), BlackRock Inc. (7.79%), Sumitomo Mitsui Trust Holdings Inc. (3.90%), State Street Corp (3.42%) and Price T Rowe Associates Inc. MD (2.21%). Insiders that own company stock include Andrew Schiermeier, Caroline Dorsa, David Lebwohl, Glenn Goddard, Jean Francois Formela, John F Crowley, John M Leonard, John M Leonard, Jose E Rivera, Jose E Rivera, Laura Sepp-Lorenzino and Perry A Karsen.
View institutional ownership trends
.

How do I buy shares of Intellia Therapeutics?

Shares of NTLA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Intellia Therapeutics' stock price today?

One share of NTLA stock can currently be purchased for approximately $48.26.

How much money does Intellia Therapeutics make?

Intellia Therapeutics (NASDAQ:NTLA) has a market capitalization of $3.80 billion and generates $33.05 million in revenue each year. The company earns $-267,890,000.00 in net income (profit) each year or ($5.87) on an earnings per share basis.

How many employees does Intellia Therapeutics have?

The company employs 485 workers across the globe.

How can I contact Intellia Therapeutics?

Intellia Therapeutics' mailing address is 40 Erie Street Suite 130, Cambridge MA, 02139. The official website for the company is www.intelliatx.com. The company can be reached via phone at (857) 285-6200 or via email at lina.li@intelliatx.com.

This page (NASDAQ:NTLA) was last updated on 11/29/2022 by MarketBeat.com Staff